Sarepta Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06 April 2017 - 7:00AM
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage
biopharmaceutical company focused on the discovery and development
of unique RNA-targeted therapeutics for the treatment of rare
neuromuscular diseases, granted an equity award on April 3, 2017 to
Catherine Stehman-Breen. The award was previously approved by the
Compensation Committee of its Board of Directors under Sarepta’s
2014 Employment Commencement Incentive Plan, as a material
inducement to Dr. Stehman-Breen’s employment as chief medical
officer. The equity award was approved in accordance with Nasdaq
Listing Rule 5635(c)(4).
Dr. Stehman-Breen received options to purchase 100,000 shares of
Sarepta's common stock. The options have an exercise price of
$29.70 per share, which is equal to the closing price of Sarepta's
common stock on April 3, 2017. One-fourth of the shares underlying
the employee’s option will vest on the one year anniversary of her
date of hire and thereafter 1/48th of the shares underlying the
option will vest monthly, such that the shares underlying the
option will be fully vested on the fourth anniversary of her date
of hire, in each case, subject to her continued employment with
Sarepta on such vesting dates.
About Sarepta Therapeutics
Sarepta Therapeutics is a commercial-stage biopharmaceutical
company focused on the discovery and development of unique
RNA-targeted therapeutics for the treatment of rare neuromuscular
diseases. The Company is primarily focused on rapidly advancing the
development of its potentially disease-modifying Duchenne muscular
dystrophy (DMD) drug candidates. For more information, please visit
us at www.sarepta.com.
Internet Posting of Information
We routinely post information that may be important to investors
in the 'For Investors' section of our website
at www.sarepta.com. We encourage investors and potential
investors to consult our website regularly for important
information about us.
Media and Investors:
Sarepta Therapeutics, Inc.
Ian Estepan, 617-274-4052
iestepan@sarepta.com
or
W2O Group
Brian Reid, 212-257-6725
breid@w2ogroup.com
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Apr 2024 to May 2024
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From May 2023 to May 2024